Roche Pharma CEO Teresa Graham outlined the company’s priorities for the coming years at the J.P. Morgan Healthcare Conference 2026: maximise the on-market portfolio to sustain growth through 2028, deliver key product launches to maintain momentum, and prepare broad entry into novel disease areas, including Alzheimer’s and obesity, via new molecular entities.
Roche said it was on track to meet its 2025 financial target, with year-to-date sales to September 2025 of CHF 35.6 billion ($44.5 billion), including CHF 18 billion ($22.5 billion) from its oncology and haematology portfolio. The marketed portfolio continues to expand, with 17 blockbuster drugs. Oncology and haematology strengths cited included breast cancer products Phesgo, Kadcyla, Perjeta and Itovebi; Tecentriq for solid tumours; Polivy and Columvi/Lunsumio for diffuse large B-cell lymphoma (DLBCL); and Hemlibra for haemophilia A.
Graham emphasised Roche’s use of partnerships and acquisitions to build and accelerate its pipeline, noting that about 60% of the company’s R&D pipeline and total drug sales involve partners. Roche expects filings for up to three new molecular entities in 2026.
A major focus is giredestrant, a next-generation selective oestrogen receptor degrader (SERD) in Phase III development for early and metastatic breast cancer. The combination of giredestrant and everolimus is at pre-registration with the US Food and Drug Administration, and an application to the European Medicines Agency is expected in 2026. Roche positions giredestrant as a potential replacement for standard endocrine therapy in ER-positive breast cancer and highlights its potential synergy with PI3K/AKT/mTOR pathway inhibitors.
Roche’s small-molecule portfolio intended to complement giredestrant includes the PI3K inhibitor Itovebi, the CDK4/2 inhibitor GDC-4198 targeting resistance to CDK4/6 inhibitors, and a brain-penetrant HER2 tyrosine kinase inhibitor, ZN-1041. Key Phase III readouts expected in 2026 include giredestrant plus palbociclib in first-line ER+/HER2- metastatic breast cancer (persevERA) and Itovebi combinations in post-CDKi hormone receptor–positive metastatic breast cancer (INAVO121) and in PIK3CA-mutant HER2+ disease with Phesgo (INAVO122).
Analyst consensus forecasts from GlobalData project giredestrant could reach $1.7 billion in sales by 2031. The oral SERD field is highly competitive: AstraZeneca’s camizestrant is in FDA pre-registration and forecast at $1.8 billion, while palazestrant (Olema Pharmaceuticals) is in Phase III and projected at $1.3 billion. Roche said clinical differentiation and in-house combination strategies will be critical to secure a leading position in the evolving HER2-/HR+ market.
Other regulatory and clinical milestones anticipated in 2026 include a potential US approval for the Lunsumio–Polivy combination in DLBCL, Phase III results for KRAS G12C inhibitor divarasib in non-small cell lung cancer (KRASCENDO 1), and a label expansion for Lunsumio into earlier lines for follicular lymphoma (CELESTIMO).
In haemophilia A, Roche highlighted NXT007, a Phase II bispecific antibody targeting coagulation factors IX and X and licensed from Chugai Pharmaceutical, as having blockbuster potential; GlobalData forecasts $760 million in sales by 2031.
Graham expressed confidence that Roche’s marketed portfolio can drive growth through 2028, supported by expected 2026 launches and positive Phase III readouts. She also outlined a diversified pipeline across oncology, haematology, immunology, neurology and ophthalmology, and said Roche aims to be a top-three player in obesity with five NMEs planned for 2026, focusing on further iterations of the incretin pathway and exploration of novel mechanisms of action.
Leave a Reply